申请人:Du Pont Merck Pharmaceutical Company
公开号:US05039706A1
公开(公告)日:1991-08-13
The invention relates to benzylamine phosphilipase A.sub.2 inhibitors, pharmaceutical compositions containing them, and methods of treating phospholipase A.sub.2 -mediated conditions in mammals by administration of a therapeutically effective amount of such a benzylamine phospholipase A.sub.2 inhibitor.
本发明涉及苄基胺磷脂酶A.sub.2抑制剂,含有它们的制药组合物,以及通过给予这种苄基胺磷脂酶A.sub.2抑制剂的治疗有效剂量来治疗哺乳动物的磷脂酶A.sub.2介导疾病的方法。